[
  {
    "ts": "2025-11-05T07:07:34+00:00",
    "headline": "Novo Cuts Outlook Citing Lower Wegovy, Ozempic Sales",
    "summary": "Novo Nordisk pared its forecast for a fourth time this year, citing lower-than-anticipated sales of its blockbuster drugs Wegovy and Ozempic. The Danish drugmaker is struggling to compete with Eli Lilly in the growing market for obesity medicines. Bloomberg's Sara Sjolin reports.",
    "url": "https://finance.yahoo.com/video/novo-cuts-outlook-citing-lower-070734151.html",
    "source": "Bloomberg",
    "provider": "yfinance",
    "raw": {
      "id": "a154678e-5ee0-36f7-bb14-614a98d2e1f0",
      "content": {
        "id": "a154678e-5ee0-36f7-bb14-614a98d2e1f0",
        "contentType": "VIDEO",
        "title": "Novo Cuts Outlook Citing Lower Wegovy, Ozempic Sales",
        "description": "Novo Nordisk pared its forecast for a fourth time this year, citing lower-than-anticipated sales of its blockbuster drugs Wegovy and Ozempic. The Danish drugmaker is struggling to compete with Eli Lilly in the growing market for obesity medicines. Bloomberg's Sara Sjolin reports.",
        "summary": "Novo Nordisk pared its forecast for a fourth time this year, citing lower-than-anticipated sales of its blockbuster drugs Wegovy and Ozempic. The Danish drugmaker is struggling to compete with Eli Lilly in the growing market for obesity medicines. Bloomberg's Sara Sjolin reports.",
        "pubDate": "2025-11-05T07:07:34Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/bloomberg_markets_video_2/48da09b73e617d3ed4db23762a76e6c5",
          "originalWidth": 1280,
          "originalHeight": 720,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1zybb2vgGgXBzqNJ7szMrA--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/bloomberg_markets_video_2/48da09b73e617d3ed4db23762a76e6c5.cf.webp",
              "width": 1280,
              "height": 720,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YicD43sE6CI_pRnJke6u5g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/bloomberg_markets_video_2/48da09b73e617d3ed4db23762a76e6c5.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Bloomberg",
          "url": "https://www.bloomberg.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/novo-cuts-outlook-citing-lower-070734151.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/novo-cuts-outlook-citing-lower-070734151.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-05T10:31:31+00:00",
    "headline": "Novo Nordisk lowers profit guidance in new CEO's maiden quarter",
    "summary": "<body><p>STORY: Novo Nordisk lowered its full-year profit and sales forecast Wednesday (November 5).</p><p>It's a sign the challenges facing the Wegovy-maker's new CEO are still a drag.</p><p>Mike Doustdar took over the Danish firm in August under pressure from investors to regain ground in the obesity drug market.</p><p>Competition from U.S. rival Eli Lilly and copycat drugs drove Novo's stock down this year.</p><p>The share price plunge and slower sales growth led to a change of CEO and board shake-up in recent months..</p><p>But Doustdar's first quarterly results showed the firm now expects full-year operating profit to grow between 4% and 7% in 2025.</p><p>That's down from an earlier forecast of between 4% and 10%.</p><p>Doustdar blamed the lower guidance on smaller growth expectations for the company's best-selling weight management and diabetes medications.&nbsp;</p><p>Total sales in the period rose 5% to $11.71 billion - below analyst forecasts.</p><p>Operating profit also fell 30% to $3.65 billion during the quarter.</p><p>The stock dropped heavily at the open on Wednesday, but recovered to trade 2% higher.</p></body>",
    "url": "https://finance.yahoo.com/video/novo-nordisk-lowers-profit-guidance-103131187.html",
    "source": "Reuters Videos",
    "provider": "yfinance",
    "raw": {
      "id": "3f5023e1-a2fd-34e7-9507-b9897030dfd4",
      "content": {
        "id": "3f5023e1-a2fd-34e7-9507-b9897030dfd4",
        "contentType": "VIDEO",
        "title": "Novo Nordisk lowers profit guidance in new CEO's maiden quarter",
        "description": "<title><body><p>STORY: Novo Nordisk lowered its full-year profit and sales forecast Wednesday (November 5).</p><p>It's a sign the challenges facing the Wegovy-maker's new CEO are still a drag.</p><p>Mike Doustdar took over the Danish firm in August under pressure from investors to regain ground in the obesity drug market.</p><p>Competition from U.S. rival Eli Lilly and copycat drugs drove Novo's stock down this year.</p><p>The share price plunge and slower sales growth led to a change of CEO and board shake-up in recent months..</p><p>But Doustdar's first quarterly results showed the firm now expects full-year operating profit to grow between 4% and 7% in 2025.</p><p>That's down from an earlier forecast of between 4% and 10%.</p><p>Doustdar blamed the lower guidance on smaller growth expectations for the company's best-selling weight management and diabetes medications. </p><p>Total sales in the period rose 5% to $11.71 billion - below analyst forecasts.</p><p>Operating profit also fell 30% to $3.65 billion during the quarter.</p><p>The stock dropped heavily at the open on Wednesday, but recovered to trade 2% higher.</p></body></title>",
        "summary": "<body><p>STORY: Novo Nordisk lowered its full-year profit and sales forecast Wednesday (November 5).</p><p>It's a sign the challenges facing the Wegovy-maker's new CEO are still a drag.</p><p>Mike Doustdar took over the Danish firm in August under pressure from investors to regain ground in the obesity drug market.</p><p>Competition from U.S. rival Eli Lilly and copycat drugs drove Novo's stock down this year.</p><p>The share price plunge and slower sales growth led to a change of CEO and board shake-up in recent months..</p><p>But Doustdar's first quarterly results showed the firm now expects full-year operating profit to grow between 4% and 7% in 2025.</p><p>That's down from an earlier forecast of between 4% and 10%.</p><p>Doustdar blamed the lower guidance on smaller growth expectations for the company's best-selling weight management and diabetes medications.&nbsp;</p><p>Total sales in the period rose 5% to $11.71 billion - below analyst forecasts.</p><p>Operating profit also fell 30% to $3.65 billion during the quarter.</p><p>The stock dropped heavily at the open on Wednesday, but recovered to trade 2% higher.</p></body>",
        "pubDate": "2025-11-05T10:31:31Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/uu/api/res/1.2/PFr3p95BBTILop.3kHXTPw--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://cf-images.us-east-1.prod.boltdns.net/v1/jit/6415665815001/f8a49872-5909-484f-9206-0e711e57bd2f/main/1280x720/35s224ms/match/image.jpg",
          "originalWidth": 1280,
          "originalHeight": 720,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/b8TyzmXpU1zHhxoG6gU2qg--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://cf-images.us-east-1.prod.boltdns.net/v1/jit/6415665815001/f8a49872-5909-484f-9206-0e711e57bd2f/main/1280x720/35s224ms/match/image.jpg.cf.webp",
              "width": 1280,
              "height": 720,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2uyH5Mgfq20piunpHHYRAQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://cf-images.us-east-1.prod.boltdns.net/v1/jit/6415665815001/f8a49872-5909-484f-9206-0e711e57bd2f/main/1280x720/35s224ms/match/image.jpg.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters Videos",
          "url": "http://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/novo-nordisk-lowers-profit-guidance-103131187.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/novo-nordisk-lowers-profit-guidance-103131187.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-05T10:00:00+00:00",
    "headline": "Novo Nordisk Stock Up After Earnings. Guidance Cut on These Weight-Loss Drug Fears.",
    "summary": "The Danish drugmaker has gone from steady to chaotic. Its fight with Pfizer to acquire Metsera is getting more heated.",
    "url": "https://www.barrons.com/articles/novo-nordisk-earnings-stock-price-997bc7ca?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "ba684ec8-e1fe-37a7-b161-5472c35e891e",
      "content": {
        "id": "ba684ec8-e1fe-37a7-b161-5472c35e891e",
        "contentType": "STORY",
        "title": "Novo Nordisk Stock Up After Earnings. Guidance Cut on These Weight-Loss Drug Fears.",
        "description": "",
        "summary": "The Danish drugmaker has gone from steady to chaotic. Its fight with Pfizer to acquire Metsera is getting more heated.",
        "pubDate": "2025-11-05T10:00:00Z",
        "displayTime": "2025-11-05T10:00:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/ba684ec8-e1fe-37a7-b161-5472c35e891e/novo-nordisk-stock-up-after.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/33cdf10977edf16fd4f87e8324176083",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xyHlGWIyozQ11qgbu0Gisw--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/33cdf10977edf16fd4f87e8324176083.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/N2uBceIjOWjhcBVcyJWYqA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/33cdf10977edf16fd4f87e8324176083.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/novo-nordisk-earnings-stock-price-997bc7ca?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-05T10:00:00+00:00",
    "headline": "XtalPi Subsidiary Ailux Announces Strategic Collaboration with Lilly to Advance Bispecific Antibody Development",
    "summary": "Ailux, an innovator in AI-powered biologics and a wholly owned subsidiary of XtalPi (2228.HK), a global leader in AI drug discovery, today announced a strategic platform-based collaboration with Eli Lilly and Company (\"Lilly\") to accelerate the discovery and development of bispecific antibodies for the treatment of various diseases.",
    "url": "https://finance.yahoo.com/news/xtalpi-subsidiary-ailux-announces-strategic-100000990.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "f6786ae9-142f-344f-91c0-b14bf081d904",
      "content": {
        "id": "f6786ae9-142f-344f-91c0-b14bf081d904",
        "contentType": "STORY",
        "title": "XtalPi Subsidiary Ailux Announces Strategic Collaboration with Lilly to Advance Bispecific Antibody Development",
        "description": "",
        "summary": "Ailux, an innovator in AI-powered biologics and a wholly owned subsidiary of XtalPi (2228.HK), a global leader in AI drug discovery, today announced a strategic platform-based collaboration with Eli Lilly and Company (\"Lilly\") to accelerate the discovery and development of bispecific antibodies for the treatment of various diseases.",
        "pubDate": "2025-11-05T10:00:00Z",
        "displayTime": "2025-11-05T10:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/096d1c8437cb84e2a88b2cfea6eea574",
          "originalWidth": 400,
          "originalHeight": 213,
          "caption": "(PRNewsfoto/XtalPi Inc.)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qKpkpx4Fq6Ilnn6KRanBeA--~B/aD0yMTM7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/096d1c8437cb84e2a88b2cfea6eea574.cf.webp",
              "width": 400,
              "height": 213,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CY.04liNkBzvC7f2zYAWMw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/096d1c8437cb84e2a88b2cfea6eea574.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/xtalpi-subsidiary-ailux-announces-strategic-100000990.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/xtalpi-subsidiary-ailux-announces-strategic-100000990.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "QNTPF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-05T10:51:06+00:00",
    "headline": "Novo Nordisk lowers profit guidance in new CEO's maiden quarter",
    "summary": "<body><p>STORY: Novo Nordisk lowered its full-year profit and sales forecast Wednesday (November 5).</p><p>It's a sign the challenges facing the Wegovy-maker's new CEO are still a drag.</p><p>Mike Doustdar took over the Danish firm in August under pressure from investors to regain ground in the obesity drug market.</p><p>Competition from U.S. rival Eli Lilly and copycat drugs drove Novo's stock down this year.</p><p>The share price plunge and slower sales growth led to a change of CEO and board shake-up in recent months..</p><p>But Doustdar's first quarterly results showed the firm now expects full-year operating profit to grow between 4% and 7% in 2025.</p><p>That's down from an earlier forecast of between 4% and 10%.</p><p>Doustdar blamed the lower guidance on smaller growth expectations for the company's best-selling weight management and diabetes medications.&nbsp;</p><p>Total sales in the period rose 5% to $11.71 billion - below analyst forecasts.</p><p>Operating profit also fell 30% to $3.65 billion during the quarter.</p><p>The stock dropped heavily at the open on Wednesday, but recovered to trade 1% higher.</p></body>",
    "url": "https://finance.yahoo.com/video/novo-nordisk-lowers-profit-guidance-105106522.html",
    "source": "Reuters Videos",
    "provider": "yfinance",
    "raw": {
      "id": "3f9b228d-977d-3d18-b788-29628a5a69c4",
      "content": {
        "id": "3f9b228d-977d-3d18-b788-29628a5a69c4",
        "contentType": "VIDEO",
        "title": "Novo Nordisk lowers profit guidance in new CEO's maiden quarter",
        "description": "<title><body><p>STORY: Novo Nordisk lowered its full-year profit and sales forecast Wednesday (November 5).</p><p>It's a sign the challenges facing the Wegovy-maker's new CEO are still a drag.</p><p>Mike Doustdar took over the Danish firm in August under pressure from investors to regain ground in the obesity drug market.</p><p>Competition from U.S. rival Eli Lilly and copycat drugs drove Novo's stock down this year.</p><p>The share price plunge and slower sales growth led to a change of CEO and board shake-up in recent months..</p><p>But Doustdar's first quarterly results showed the firm now expects full-year operating profit to grow between 4% and 7% in 2025.</p><p>That's down from an earlier forecast of between 4% and 10%.</p><p>Doustdar blamed the lower guidance on smaller growth expectations for the company's best-selling weight management and diabetes medications. </p><p>Total sales in the period rose 5% to $11.71 billion - below analyst forecasts.</p><p>Operating profit also fell 30% to $3.65 billion during the quarter.</p><p>The stock dropped heavily at the open on Wednesday, but recovered to trade 1% higher.</p></body></title>",
        "summary": "<body><p>STORY: Novo Nordisk lowered its full-year profit and sales forecast Wednesday (November 5).</p><p>It's a sign the challenges facing the Wegovy-maker's new CEO are still a drag.</p><p>Mike Doustdar took over the Danish firm in August under pressure from investors to regain ground in the obesity drug market.</p><p>Competition from U.S. rival Eli Lilly and copycat drugs drove Novo's stock down this year.</p><p>The share price plunge and slower sales growth led to a change of CEO and board shake-up in recent months..</p><p>But Doustdar's first quarterly results showed the firm now expects full-year operating profit to grow between 4% and 7% in 2025.</p><p>That's down from an earlier forecast of between 4% and 10%.</p><p>Doustdar blamed the lower guidance on smaller growth expectations for the company's best-selling weight management and diabetes medications.&nbsp;</p><p>Total sales in the period rose 5% to $11.71 billion - below analyst forecasts.</p><p>Operating profit also fell 30% to $3.65 billion during the quarter.</p><p>The stock dropped heavily at the open on Wednesday, but recovered to trade 1% higher.</p></body>",
        "pubDate": "2025-11-05T10:51:06Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/uu/api/res/1.2/sH3SMkJD_hRojVzy6n3UTA--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://cf-images.us-east-1.prod.boltdns.net/v1/jit/6415665815001/28e62c04-bdf4-4803-8034-6dbdbb51c909/main/1280x720/35s224ms/match/image.jpg",
          "originalWidth": 1280,
          "originalHeight": 720,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fJSjhnaM9JKcF.yXkn.jWg--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://cf-images.us-east-1.prod.boltdns.net/v1/jit/6415665815001/28e62c04-bdf4-4803-8034-6dbdbb51c909/main/1280x720/35s224ms/match/image.jpg.cf.webp",
              "width": 1280,
              "height": 720,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/PkRgqktCwY_5O5ws27Oonw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://cf-images.us-east-1.prod.boltdns.net/v1/jit/6415665815001/28e62c04-bdf4-4803-8034-6dbdbb51c909/main/1280x720/35s224ms/match/image.jpg.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters Videos",
          "url": "http://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/novo-nordisk-lowers-profit-guidance-105106522.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/novo-nordisk-lowers-profit-guidance-105106522.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-05T13:06:00+00:00",
    "headline": "Novo Nordisk Stock Falls After Earnings. It Cut Guidance on These Fears.",
    "summary": "The Danish drugmaker has gone from steady to chaotic. Its fight with Pfizer to acquire Metsera is getting more heated.",
    "url": "https://www.barrons.com/articles/novo-nordisk-earnings-stock-price-997bc7ca?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "ba684ec8-e1fe-37a7-b161-5472c35e891e",
      "content": {
        "id": "ba684ec8-e1fe-37a7-b161-5472c35e891e",
        "contentType": "STORY",
        "title": "Novo Nordisk Stock Falls After Earnings. It Cut Guidance on These Fears.",
        "description": "",
        "summary": "The Danish drugmaker has gone from steady to chaotic. Its fight with Pfizer to acquire Metsera is getting more heated.",
        "pubDate": "2025-11-05T13:06:00Z",
        "displayTime": "2025-11-05T13:06:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/ba684ec8-e1fe-37a7-b161-5472c35e891e/novo-nordisk-stock-falls.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/33cdf10977edf16fd4f87e8324176083",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xyHlGWIyozQ11qgbu0Gisw--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/33cdf10977edf16fd4f87e8324176083.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/N2uBceIjOWjhcBVcyJWYqA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/33cdf10977edf16fd4f87e8324176083.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/novo-nordisk-earnings-stock-price-997bc7ca?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-05T12:45:00+00:00",
    "headline": "Citigroup Says This Obesity Drugmaker's Stock Is Now a Buy",
    "summary": "The bank's lead analyst recognizes the importance of getting in early with potentially game-changing drug development.",
    "url": "https://www.fool.com/investing/2025/11/05/citigroup-says-this-obesity-drugmakers-stock-is/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "eba16557-885c-36d6-956c-d8ac6e56fc20",
      "content": {
        "id": "eba16557-885c-36d6-956c-d8ac6e56fc20",
        "contentType": "STORY",
        "title": "Citigroup Says This Obesity Drugmaker's Stock Is Now a Buy",
        "description": "",
        "summary": "The bank's lead analyst recognizes the importance of getting in early with potentially game-changing drug development.",
        "pubDate": "2025-11-05T12:45:00Z",
        "displayTime": "2025-11-05T12:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/c4395eb16bf9edea6ba3a4b6319bf781",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "Work being done in a biopharmaceutical lab.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_4i4E6SvyoKOlxexqaCPdQ--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/c4395eb16bf9edea6ba3a4b6319bf781.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MGkIBwJeF6a.02mqTAlfKw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/c4395eb16bf9edea6ba3a4b6319bf781.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/11/05/citigroup-says-this-obesity-drugmakers-stock-is/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/citigroup-says-obesity-drugmakers-stock-124500033.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIOA"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-05T12:00:00+00:00",
    "headline": "XtalPi Subsidiary Ailux Announces Strategic Collaboration with Lilly to Advance Bispecific Antibody Development",
    "summary": "Ailux, an innovator in AI-powered biologics and a wholly owned subsidiary of XtalPi (2228.HK), a global leader in AI drug discovery, today announced a strategic platform-based collaboration with Eli Lilly and Company (\"Lilly\") to accelerate the discovery and development of bispecific antibodies for the treatment of various diseases.",
    "url": "https://finance.yahoo.com/news/xtalpi-subsidiary-ailux-announces-strategic-120000266.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "285471fe-cc12-34cb-89d9-3c564795f835",
      "content": {
        "id": "285471fe-cc12-34cb-89d9-3c564795f835",
        "contentType": "STORY",
        "title": "XtalPi Subsidiary Ailux Announces Strategic Collaboration with Lilly to Advance Bispecific Antibody Development",
        "description": "",
        "summary": "Ailux, an innovator in AI-powered biologics and a wholly owned subsidiary of XtalPi (2228.HK), a global leader in AI drug discovery, today announced a strategic platform-based collaboration with Eli Lilly and Company (\"Lilly\") to accelerate the discovery and development of bispecific antibodies for the treatment of various diseases.",
        "pubDate": "2025-11-05T12:00:00Z",
        "displayTime": "2025-11-05T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/0d7453de08bdebf74e9984f847129f0e",
          "originalWidth": 400,
          "originalHeight": 132,
          "caption": "Ailux logo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/S532.K4AH8LvlkwO8nXO5Q--~B/aD0xMzI7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/0d7453de08bdebf74e9984f847129f0e.cf.webp",
              "width": 400,
              "height": 132,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9M84t8lpQ8CWJiP6IkH2kg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/0d7453de08bdebf74e9984f847129f0e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/xtalpi-subsidiary-ailux-announces-strategic-120000266.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/xtalpi-subsidiary-ailux-announces-strategic-120000266.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-05T11:37:14+00:00",
    "headline": "Eli Lilly asks European nations to scrap clawback taxes, FT says",
    "summary": "Eli Lilly (LLY) has asked European nations to discard clawback taxes on drug sales, Hannah Kuchler of The Financial Times reports. As the Trump administration pushes for a policy that would lower drug prices in the U.S. to match the cheapest levels in other developed nations, Lilly CEO David Ricks said the company will lower U.S. costs while raising them in Europe to equalize the drug prices. The pharma industry has been dealing with UK’s clawback tax, where a certain percent of revenue above a",
    "url": "https://finance.yahoo.com/news/eli-lilly-asks-european-nations-113714909.html",
    "source": "TipRanks",
    "provider": "yfinance",
    "raw": {
      "id": "f15bb4c1-e3d1-3c64-b7fe-3963c95eb72b",
      "content": {
        "id": "f15bb4c1-e3d1-3c64-b7fe-3963c95eb72b",
        "contentType": "STORY",
        "title": "Eli Lilly asks European nations to scrap clawback taxes, FT says",
        "description": "",
        "summary": "Eli Lilly (LLY) has asked European nations to discard clawback taxes on drug sales, Hannah Kuchler of The Financial Times reports. As the Trump administration pushes for a policy that would lower drug prices in the U.S. to match the cheapest levels in other developed nations, Lilly CEO David Ricks said the company will lower U.S. costs while raising them in Europe to equalize the drug prices. The pharma industry has been dealing with UK’s clawback tax, where a certain percent of revenue above a",
        "pubDate": "2025-11-05T11:37:14Z",
        "displayTime": "2025-11-05T11:37:14Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/tipranks_452/060c7819ab2e6aac03de78d24e089052",
          "originalWidth": 192,
          "originalHeight": 192,
          "caption": "https://www.tipranks.com/news/the-fly/eli-lilly-asks-european-nations-to-scrap-clawback-taxes-ft-says-thefly",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vZK3M5BXOPYNoopjKe3ucA--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/060c7819ab2e6aac03de78d24e089052.cf.webp",
              "width": 192,
              "height": 192,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KMXErhC4t58oQ8xCJHHKJg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/060c7819ab2e6aac03de78d24e089052.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "TipRanks",
          "url": "https://www.tipranks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-asks-european-nations-113714909.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-asks-european-nations-113714909.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-05T11:30:00+00:00",
    "headline": "This Company Now Has the World's No. 1 Drug. Should You Invest $1,000?",
    "summary": "Lilly's GLP-1 drug became the best-selling drug on Earth in the third quarter.",
    "url": "https://www.fool.com/investing/2025/11/05/this-company-now-has-the-worlds-1-drug-should-you/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "6e33cc9a-ad94-315d-af9f-d07c485837c8",
      "content": {
        "id": "6e33cc9a-ad94-315d-af9f-d07c485837c8",
        "contentType": "STORY",
        "title": "This Company Now Has the World's No. 1 Drug. Should You Invest $1,000?",
        "description": "",
        "summary": "Lilly's GLP-1 drug became the best-selling drug on Earth in the third quarter.",
        "pubDate": "2025-11-05T11:30:00Z",
        "displayTime": "2025-11-05T11:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/c93322caee68cd60d7e378826eec5ead",
          "originalWidth": 1400,
          "originalHeight": 787,
          "caption": "Researchers in a healthcare lab.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vQaFXbVrdqwTtTiCGTAeYg--~B/aD03ODc7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/c93322caee68cd60d7e378826eec5ead.cf.webp",
              "width": 1400,
              "height": 787,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Eu5F7MJKGGf.XrYaJxbS2A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/c93322caee68cd60d7e378826eec5ead.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/11/05/this-company-now-has-the-worlds-1-drug-should-you/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/company-now-worlds-no-1-113000051.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-05T13:36:36+00:00",
    "headline": "Novo Nordisk cuts sales and profits guidance amid obesity drug competition",
    "summary": "The boss of the Wegovy firm linked its reduced guidance to the market for weight-loss treatments being ‘more competitive than ever’.",
    "url": "https://uk.finance.yahoo.com/news/novo-nordisk-cuts-sales-profits-133636909.html",
    "source": "PA Media: Money",
    "provider": "yfinance",
    "raw": {
      "id": "2e74de83-59ce-31b0-b542-78ceab7f7e6b",
      "content": {
        "id": "2e74de83-59ce-31b0-b542-78ceab7f7e6b",
        "contentType": "STORY",
        "title": "Novo Nordisk cuts sales and profits guidance amid obesity drug competition",
        "description": "",
        "summary": "The boss of the Wegovy firm linked its reduced guidance to the market for weight-loss treatments being ‘more competitive than ever’.",
        "pubDate": "2025-11-05T13:36:36Z",
        "displayTime": "2025-11-05T13:36:36Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/snappa.ukfinance/0eff77e8e90d03342ca1d57e13121e12",
          "originalWidth": 5372,
          "originalHeight": 3022,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7bvBmB1.uPLds6tUI8Ledg--~B/aD0zMDIyO3c9NTM3MjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/snappa.ukfinance/0eff77e8e90d03342ca1d57e13121e12.cf.webp",
              "width": 5372,
              "height": 3022,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xWgt0WcAjZA5pXDipVLPtg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/snappa.ukfinance/0eff77e8e90d03342ca1d57e13121e12.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PA Media: Money",
          "url": "https://www.pressassociation.com/"
        },
        "canonicalUrl": {
          "url": "https://uk.finance.yahoo.com/news/novo-nordisk-cuts-sales-profits-133636909.html",
          "site": "finance",
          "region": "GB",
          "lang": "en-GB"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-cuts-sales-profits-133636909.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]